Quinn Opportunity Partners LLC Arbutus Biopharma Corp Transaction History
Quinn Opportunity Partners LLC
- $939 Million
- Q3 2024
A detailed history of Quinn Opportunity Partners LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 235,132 shares of ABUS stock, worth $799,448. This represents 0.1% of its overall portfolio holdings.
Number of Shares
235,132
Previous 165,132
42.39%
Holding current value
$799,448
Previous $510,000
77.45%
% of portfolio
0.1%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding ABUS
# of Institutions
161Shares Held
99.7MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$73.8 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$43.8 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$30.3 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$28.5 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $510M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...